Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes

Sam Salman; Julie Hibbert; Madhu Page-Sharp; Laurens Manning; Karen Simmer; Dorota A. Doherty; Sanjay Patole; Kevin T. Batty; Tobias Strunk

doi:10.1111/bcp.13775

Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes

Sam Salman, Julie Hibbert, Madhu Page-Sharp, Laurens Manning, Karen Simmer, Dorota A. Doherty, Sanjay Patole, Kevin T. Batty, Tobias Strunk

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Aims Infection-induced inflammation is associated with adverse long-term outcomes in preterm infants. Pentoxifylline (PTX) is a candidate for adjunct immunomodulatory therapy in preterm infants with late-onset sepsis (LOS) and necrotizing enterocolitis (NEC), but pharmacokinetic data in this population are extremely limited. This study aims to characterize the pharmacokinetic properties of intravenous PTX and its metabolites in preterm infants. Method An open label pilot clinical study of intravenous PTX as an adjunct therapy in preterm infants (gestation

Original language	English
Pages (from-to)	147-159
Number of pages	13
Journal	British Journal of Clinical Pharmacology
Volume	85
Issue number	1
DOIs	https://doi.org/10.1111/bcp.13775
Publication status	Published - Jan 2019

Access to Document

10.1111/bcp.13775

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303212/

Fingerprint

Dive into the research topics of 'Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes'. Together they form a unique fingerprint.

Cite this

Salman, S., Hibbert, J., Page-Sharp, M., Manning, L., Simmer, K., Doherty, D. A., Patole, S., Batty, K. T., & Strunk, T. (2019). Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. British Journal of Clinical Pharmacology, 85(1), 147-159. https://doi.org/10.1111/bcp.13775

Salman, Sam ; Hibbert, Julie ; Page-Sharp, Madhu et al. / Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis : a pilot study incorporating clinical outcomes. In: British Journal of Clinical Pharmacology. 2019 ; Vol. 85, No. 1. pp. 147-159.

@article{8f3ad9cb601245e89b95bcaea263ef43,

title = "Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes",

abstract = "Aims Infection-induced inflammation is associated with adverse long-term outcomes in preterm infants. Pentoxifylline (PTX) is a candidate for adjunct immunomodulatory therapy in preterm infants with late-onset sepsis (LOS) and necrotizing enterocolitis (NEC), but pharmacokinetic data in this population are extremely limited. This study aims to characterize the pharmacokinetic properties of intravenous PTX and its metabolites in preterm infants. Method An open label pilot clinical study of intravenous PTX as an adjunct therapy in preterm infants (gestation",

keywords = "late-onset sepsis, lisofylline, necrotizing enterocolitis, pentoxifylline, population pharmacokinetics, preterm infant, INFLAMMATION, INJURY, BLOOD",

author = "Sam Salman and Julie Hibbert and Madhu Page-Sharp and Laurens Manning and Karen Simmer and Doherty, {Dorota A.} and Sanjay Patole and Batty, {Kevin T.} and Tobias Strunk",

year = "2019",

month = jan,

doi = "10.1111/bcp.13775",

language = "English",

volume = "85",

pages = "147--159",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "John Wiley & Sons",

number = "1",

}

Salman, S , Hibbert, J, Page-Sharp, M, Manning, L , Simmer, K , Doherty, DA , Patole, S, Batty, KT & Strunk, T 2019, 'Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes', British Journal of Clinical Pharmacology, vol. 85, no. 1, pp. 147-159. https://doi.org/10.1111/bcp.13775

Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. / Salman, Sam ; Hibbert, Julie; Page-Sharp, Madhu et al.
In: British Journal of Clinical Pharmacology, Vol. 85, No. 1, 01.2019, p. 147-159.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis

T2 - a pilot study incorporating clinical outcomes

AU - Salman, Sam

AU - Hibbert, Julie

AU - Page-Sharp, Madhu

AU - Manning, Laurens

AU - Simmer, Karen

AU - Doherty, Dorota A.

AU - Patole, Sanjay

AU - Batty, Kevin T.

AU - Strunk, Tobias

PY - 2019/1

Y1 - 2019/1

N2 - Aims Infection-induced inflammation is associated with adverse long-term outcomes in preterm infants. Pentoxifylline (PTX) is a candidate for adjunct immunomodulatory therapy in preterm infants with late-onset sepsis (LOS) and necrotizing enterocolitis (NEC), but pharmacokinetic data in this population are extremely limited. This study aims to characterize the pharmacokinetic properties of intravenous PTX and its metabolites in preterm infants. Method An open label pilot clinical study of intravenous PTX as an adjunct therapy in preterm infants (gestation

AB - Aims Infection-induced inflammation is associated with adverse long-term outcomes in preterm infants. Pentoxifylline (PTX) is a candidate for adjunct immunomodulatory therapy in preterm infants with late-onset sepsis (LOS) and necrotizing enterocolitis (NEC), but pharmacokinetic data in this population are extremely limited. This study aims to characterize the pharmacokinetic properties of intravenous PTX and its metabolites in preterm infants. Method An open label pilot clinical study of intravenous PTX as an adjunct therapy in preterm infants (gestation

KW - late-onset sepsis

KW - lisofylline

KW - necrotizing enterocolitis

KW - pentoxifylline

KW - population pharmacokinetics

KW - preterm infant

KW - INFLAMMATION

KW - INJURY

KW - BLOOD

U2 - 10.1111/bcp.13775

DO - 10.1111/bcp.13775

M3 - Article

C2 - 30281170

SN - 0306-5251

VL - 85

SP - 147

EP - 159

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 1

ER -

Salman S , Hibbert J, Page-Sharp M, Manning L , Simmer K , Doherty DA et al. Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. British Journal of Clinical Pharmacology. 2019 Jan;85(1):147-159. doi: 10.1111/bcp.13775